Article (Scientific journals)
Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy.
FOIDART, Pierre; Yip, Cassandre; Radermacher, Jean et al.
2019In Clinical Cancer Research
Peer Reviewed verified by ORBi
 

Files


Full Text
Foidart P 2019.full.pdf
Publisher postprint (1.9 MB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Triple Negative Breast Cancer; MT4-MMP; EGFR
Abstract :
[en] Abstract Purpose: Here, we investigated the clinical relevance of an unprecedented combination of three biomarkers in triple-negative breast cancer (TNBC), both in human samples and in patient-derived xenografts of TNBC (PDX-TNBC): EGFR, its recently identified partner (MT4-MMP), and retinoblastoma protein (RB).Experimental Design: IHC analyses were conducted on human and PDX-TNBC samples to evaluate the production of the three biomarkers. The sensitivity of cancer cells expressing or not MT4-MMP to anti-EGFR (erlotinib) or anti-CDK4/6 inhibitor (palbociclib) was evaluated in vitro in 2D and 3D proliferation assays and in vivo using xenografts and PDX-TNBC displaying different RB, MT4-MMP, and EGFR status after single (erlotinib or palbociclib) or combined (erlotinib + palbociclib) treatments.Results: EGFR and MT4-MMP were coexpressed in >70% of TNBC samples and PDX-TNBC, among which approximately 60% maintained RB expression. Notably, approximately 50% of all TNBC and PDX-TNBC expressed the three biomarkers. Single erlotinib and palbociclib treatments drastically reduced the in vitro proliferation of cells expressing EGFR and MT4-MMP when compared with control cells. Both TNBC xenografts and PDX expressing MT4-MMP, EGFR, and RB, but not PDX-TNBC with RB loss, were sensitive to erlotinib and palbociclib with an additive effect of combination therapy. Moreover, this combination was efficient in another PDX-TNBC expressing the three biomarkers and resistant to erlotinib alone.Conclusions: We defined a new association of three biomarkers (MT4-MMP/EGFR/RB) expressed together in 50% of TNBC and demonstrated its usefulness to predict the TNBC response to anti-EGFR and anti-CDK4/6 drugs used in single or combined therapy.
Disciplines :
Oncology
Author, co-author :
FOIDART, Pierre ;  Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'oncologie médicale
Yip, Cassandre ;  Université de Liège - ULiège > Département des sciences cliniques > Labo de biologie des tumeurs et du développement
Radermacher, Jean
Blacher, Silvia ;  Université de Liège - ULiège > Département des sciences cliniques > Labo de biologie des tumeurs et du développement
Lienard, Mehdi ;  Université de Liège - ULiège > Département des sciences cliniques > Labo de biologie des tumeurs et du développement
MONTERORUIZ, Laetitia ;  Centre Hospitalier Universitaire de Liège - CHU > Département ULiège > GIGA
Maquoi, Erik  ;  Université de Liège - ULiège > Département des sciences cliniques > Labo de biologie des tumeurs et du développement
Montaudon, Elodie
Chateau-Joubert, Sophie
COLLIGNON, Joëlle  ;  Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'oncologie médicale
Coibion, Michel
Jossa, Veronique
Marangoni, Elisabetta
Noël, Agnès ;  Université de Liège - ULiège > Département des sciences cliniques > Labo de biologie des tumeurs et du développement
Sounni, Nor Eddine   ;  Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie cellulaire et moléculaire
JERUSALEM, Guy   ;  Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'oncologie médicale
More authors (6 more) Less
 These authors have contributed equally to this work.
Language :
English
Title :
Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy.
Publication date :
2019
Journal title :
Clinical Cancer Research
ISSN :
1078-0432
eISSN :
1557-3265
Publisher :
American Association for Cancer Research, United States - Pennsylvania
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 28 February 2019

Statistics


Number of views
110 (38 by ULiège)
Number of downloads
10 (10 by ULiège)

Scopus citations®
 
40
Scopus citations®
without self-citations
36
OpenCitations
 
30

Bibliography


Similar publications



Contact ORBi